Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2001-11-07
2008-11-04
O'Hara, Eileen B. (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C435S328000, C435S344100
Reexamination Certificate
active
07446179
ABSTRACT:
The present invention relates to a genetically engineered, CD19-specific chimeric T cell receptor and to immune cells expressing the chimeric receptor The present invention also relates to the use of such cells for cellular immunotherapy of CD9+malignancies and for abrogating any untoward B cell function. The chimeric receptor is a single chain scFvFc:ζ receptor where scFvFc designates the extracellular domain, scFv designates the VHand VLchains of a single chain monoclonal antibody to CD19, Fc represents at least part of a constant region of an IgG1, and ζ represents the intracellular signaling domain of the zeta chain of human CD3. The extracellular domain scFvFc and the intracellular domain ζ are linked by a transmembrane domain such as the transmembrane domain of CD4. In one aspect, the chimeric receptor comprises amino acids 23-634 of SEQ I DNO:2. The present invention further relates to a method of making a redirected T cell expressing a chimeric T cell receptor by electroporation using naked DNA encoding the receptor.
REFERENCES:
patent: 5359046 (1994-10-01), Capon et al.
patent: 5712149 (1998-01-01), Roberts
patent: 6410319 (2002-06-01), Raubitschek et al.
patent: WO 94/11026 (1994-05-01), None
patent: WO 97/23613 (1997-07-01), None
patent: WO 98/41613 (1998-09-01), None
patent: WO 99/54440 (1999-10-01), None
patent: WO 00/23573 (2000-04-01), None
patent: WO 00/23573 (2000-04-01), None
patent: WO 00/31239 (2000-06-01), None
Jensen et. al. CD20 is a molecular target for . . . implications for cellular immunotherapy of CD20+ malignancy. Biology of Blood and Marrow Transplantation. 1998; 4: 75-8.
Stamenkovic et. al. CD19, the earliest differentiation antigen of the B cell lineage . . . epstein-barr virus-related cytoplasmic tail. J. Exp. Med. 1988; 168: 1205-1210.
Whitlow et al., Protein Eng. Nov. 1993;6(8):989-95.
Jensen, M et al. “CD20 Is A Molecular Target For scFvFc:ζ Receptor Redirected T Cells: Implications For Cellular Immunotherapy of CD2+Malignancy,”Biology of Blood and Marrow Transplantation, 4:75-83, 1998.
Abken, H. et al. “Chimeric T-Cell Receptors: Highly Specific Tools To Target Cytotoxic T-Lymphocytes To Tumour Cells,”Cancer Treatment Reviews, 23:97-112, 1997.
Nicholson, Ian C. et al. “Construction And Characterisation Of A Functional CD19 Specific Single Chain Fv Fragment . . . ,”Molecular Immunology, vol. 34, No. 16-17, 1157-1165, 1997.
Amstutz, H., et al. “Production And Characterization Of A Mouse/Human Chimeric Antibody Directed Against Human Neuroblastoma,”, Int. J. Cancer, 53: 147-152, 1993.
Kipriyanov, S. M. et al. “Bispecific CD3 × CD19 Diabody For T Cell-Mediated Lysis of Malignant Human B Cells”,International Journal of Cancer, vol. 77, No. 5, 763-771, 1998.
Abken, H. et al. “Can Combined T-cell And Antibody-Based Immunotherapy Outsmart Tumor Cells?,”Immunology Today, vol. 19, No. 1, 1-5, 1998.
Haisma, H. et al. “Construction And Characterization Of A Fusion Protein Of Single-Chain Anti-CD20 Antibody And Human Beta-Glucuronidase For Antibody-Directed Enzyme Prodrug Therapy,”Blood, vol. 92, No. 1, 184-190, 1998.
Anderson, D. et al. “Targeted Anti-Cancer Therapy Using Rituximab, A Chimaeric Anti-CD20 Antibody (IDEC-C2B8) In The Treatment of Non-Hodgkin's B-Cell Lymphoma”,Biochemical Society Transactions, vol. 25, 705-8, 1997.
Forman Stephen
Jensen Micahel C.
Raubitschek Andrew
City of Hope
O'Hara Eileen B.
Rothwell Figg Ernst & Manbeck p.c.
Skelding Zachary
LandOfFree
CD19-specific chimeric T cell receptor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with CD19-specific chimeric T cell receptor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and CD19-specific chimeric T cell receptor will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4036505